A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence - Scorecard - MDSpire

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence

  • By

  • Jonathan I. Silverberg

  • Alan D. Irvine

  • Peter Foley

  • James Del Rosso

  • Luis Puig

  • Linda Stein Gold

  • Masahiro Kamata

  • Andreas Wollenberg

  • H. Chih-ho Hong

  • Chia-Yu Chu

  • Yousef Binamer

  • Martin Dossenbach

  • Marta Casillas

  • Gaia Gallo

  • Buelent Akmaz

  • Kim Rand

  • Raj Chovatiya

  • June 17, 2026

  • 0 min

Share

Clinical Scorecard: Evaluating Durability in Atopic Dermatitis: An Indirect Analysis of Lebrikizumab, Dupilumab, and Tralokinumab's Efficacy Amidst Varied Treatment Adherence

At a Glance

CategoryDetail
ConditionAtopic Dermatitis
Key MechanismsBiologic therapies targeting inflammatory pathways
Target PopulationAdults and adolescents with moderate-to-severe atopic dermatitis
Care SettingClinical trials and real-world settings

Key Highlights

  • Lebrikizumab showed comparable or superior long-term efficacy to dupilumab and superior to tralokinumab.
  • The Durability Index (DI) combines on-drug efficacy and off-drug durability of response.
  • Treatment interruptions are common in real-world management of atopic dermatitis.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of atopic dermatitis based on clinical criteria including skin lesions and pruritus.

Management

  • Consider biologic therapies such as lebrikizumab, dupilumab, and tralokinumab for moderate-to-severe cases.

Monitoring & Follow-up

  • Monitor treatment adherence and response rates, especially during maintenance phases.

Risks

  • Potential for treatment interruptions affecting long-term outcomes.

Patient & Prescribing Data

Adults and adolescents with moderate-to-severe atopic dermatitis.

Lebrikizumab may provide better long-term efficacy compared to other biologics.

Clinical Best Practices

  • Utilize the Durability Index to assess long-term treatment performance.
  • Evaluate patient adherence to optimize treatment outcomes.

Related Resources & Content

Original Source(s)

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence

  • by Jonathan I. Silverberg, Alan D. Irvine, Peter Foley, James Del Rosso, Luis Puig, Linda Stein Gold, Masahiro Kamata, Andreas Wollenberg, H. Chih-ho Hong, Chia-Yu Chu, Yousef Binamer, Martin Dossenbach, Marta Casillas, Gaia Gallo, Buelent Akmaz, Kim Rand, Raj Chovatiya

  • June 17, 2026

Related Content

Autohemotherapy combined with other external treatments of Traditional Chinese Medicine for chronic urticaria: a systematic review and meta-analysis

Beyond Drainage: Clinical–Ultrasound Correlation Supports a Broader Definition of the Active Tunnel in Hidradenitis Suppurativa

Medical visual question answering with multimodal: a systematic mini review (2023–2026)